Ping Hsun Chen 2019 05 A Brand Name Drug Company May Violate Section Two of the Sherman Act by Mislabeling a Submitted Patent in the Orange Book An Implication from In Re Actos End Payor Antitrust Litigation 848 F 3d 89 2d Cir 2017 Brooklyn Journal of Corporate Financial Commercial Law Vol 13 No 2 pp 395 416 Westlaw 為通訊作者

Year	2019
Authors	PING-HSUN CHEN
Paper Title	Ping-Hsun Chen, 2019.05, 'A Brand-Name Drug Company May Violate Section Two of the Sherman Act by Mislabeling a Submitted Patent in the Orange Book: An Implication from In Re Actos End-Payor Antitrust Litigation, 848 F.3d 89 (2d Cir. 2017), ' Brooklyn Journal of Corporate, Financial & Commercial Law, Vol.13, No.2, pp.395-416.(Westlaw)(為通訊作者)
Vol.No	422608
Date of Publication	2019-05-01